Previous researches in CLL indicated that BTK inhibitor ibrutinib could largely increase CYLD activity through increasing CYLD miRNA transcription, which could inhibit cells proliferation in CLL [25]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.